Ireland's Amarin Q2 revenue falls on lower licensing payments

Amarin

29/07/2026 12:11

Overview
Ireland-based cardiovascular drug maker's Q2 net revenue fell 42% yr/yr due to prior-year licensing payment
Q2 operating expenses dropped 59% yr/yr as cost savings plan completed
Company reported positive cash flow for third straight quarter and expects further international growth

Outlook
Amarin expects continued growth in international markets for the remainder of 2026
Company expects U.S. VASCEPA volumes to remain consistent throughout FY 2026
Amarin expects positive cash flow generation and cash to grow by 10% by year-end 2026

Result Drivers
LICENSING PAYMENT IMPACT - Net revenue decline mainly due to absence of $25 mln upfront payment from Recordati in prior-year quarter
GENERIC COMPETITION - Modest decline in U.S. sales driven by continued generic competition and net pricing pressure, partly offset by higher branded VASCEPA demand
COST SAVINGS - Operating expenses fell 59% yr/yr as company completed $70 mln annual cost savings initiative

Company press release: ID:nGNX4k8NjK

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Operating Expenses
 
$27 mln
 

Analyst Coverage
The one available analyst rating on the shares is "sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Reuters Recommended Reads
July 28 - Italy's Recordati H1 revenue rises 6.6% on rare diseases segment growth
July 29 - Boston Scientific Q2 results beat estimates on cardiovascular strength 
July 27 - AstraZeneca Q2 revenue rises 6% on demand for its cancer therapies

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)